ValuEngine upgraded shares of Hologic (NASDAQ:HOLX) from a sell rating to a hold rating in a report published on Wednesday, ValuEngine reports.

A number of other equities research analysts also recently issued reports on the stock. Bank of America raised shares of Hologic from a neutral rating to a buy rating and upped their price target for the company from $54.00 to $59.00 in a research note on Thursday, September 26th. BTIG Research reaffirmed a buy rating and set a $52.00 price target on shares of Hologic in a research note on Thursday, August 1st. Canaccord Genuity reduced their target price on shares of Hologic from $52.00 to $50.00 and set a hold rating on the stock in a research note on Monday, November 11th. BidaskClub downgraded shares of Hologic from a hold rating to a sell rating in a research note on Thursday, November 7th. Finally, Zacks Investment Research raised shares of Hologic from a hold rating to a buy rating and set a $54.00 target price on the stock in a research note on Friday, August 16th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the company. Hologic currently has a consensus rating of Hold and an average price target of $51.19.

Hologic stock traded up $0.31 during mid-day trading on Wednesday, reaching $49.50. 3,500,200 shares of the company’s stock traded hands, compared to its average volume of 1,875,415. The company has a market cap of $12.60 billion, a price-to-earnings ratio of 20.37, a PEG ratio of 2.06 and a beta of 0.76. The stock has a 50 day moving average of $48.24 and a two-hundred day moving average of $48.11. The company has a quick ratio of 1.26, a current ratio of 1.68 and a debt-to-equity ratio of 1.22. Hologic has a 12-month low of $37.48 and a 12-month high of $52.19.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $0.65 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.65. The company had revenue of $865.80 million for the quarter, compared to the consensus estimate of $846.54 million. Hologic had a negative net margin of 1.19% and a positive return on equity of 29.14%. Hologic’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.58 earnings per share. As a group, sell-side analysts forecast that Hologic will post 2.63 earnings per share for the current year.

In other Hologic news, insider Peter J. Valenti III sold 7,766 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $49.14, for a total transaction of $381,621.24. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 194,396 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $45.91, for a total transaction of $8,924,720.36. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Grantham Mayo Van Otterloo & Co. LLC bought a new position in Hologic during the 2nd quarter worth about $325,000. McGuire Investment Group LLC grew its holdings in Hologic by 20.6% during the 2nd quarter. McGuire Investment Group LLC now owns 96,190 shares of the medical equipment provider’s stock worth $4,619,000 after acquiring an additional 16,446 shares in the last quarter. Fox Run Management L.L.C. bought a new position in Hologic during the 2nd quarter worth about $576,000. Paloma Partners Management Co bought a new position in Hologic during the 2nd quarter worth about $4,243,000. Finally, Natixis bought a new position in Hologic during the 2nd quarter worth about $4,191,000. Institutional investors own 96.98% of the company’s stock.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Read More: Outstanding Shares and The Effect on Share Price

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.